1.19
-0.28(-19.05%)
Currency In USD
| Previous Close | 1.47 |
| Open | 1.44 |
| Day High | 1.47 |
| Day Low | 1.18 |
| 52-Week High | 3.83 |
| 52-Week Low | 1 |
| Volume | 686,809 |
| Average Volume | 198,606 |
| Market Cap | 42.82M |
| PE | -0.58 |
| EPS | -2.04 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.76 |
| Change | -0.28 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $67.65 as of April 30, 2025 at a share price of $1.19. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 2 years ago, it would be worth $220.37 as of April 30, 2025 at a share price of $1.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 02, 2025 12:00 PM GMT
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced t
Immuneering Corporation Announces Grant of Inducement Award
GlobeNewswire Inc.
Mar 21, 2025 8:30 PM GMT
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announ
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
GlobeNewswire Inc.
Mar 20, 2025 11:00 AM GMT
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in